Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
23 Results for "
including psoriasis
" in MedChemExpress (MCE) Product Catalog:
Products (23)
23 Results for "including psoriasis" in MCE Product Catalog:
3
Target:
Research Areas:
Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function .
3
3 Cited Publications
Synonyms: Hyperforin DCHA
Target:
1
1 Cited Publications
Cat. No.: HY-B1616
CAS No.: 25122-57-0
Target:
Research Areas:
Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
1
1 Cited Publications
Cat. No.: HY-155978A
Purity: 99.80%
Target:
Research Areas:
RDN2150 TFA is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 TFA inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 TFA can be used for psoriasis-related research .
Cat. No.: HY-P99754
CAS No.: 1796570-08-5
Synonyms: BCD-085
Target:
Research Areas:
Cat. No.: HY-116330
CAS No.: 11079-53-1
Category:
Plant Hyperlcurn perforatum L. Extract Anti-inflammation/Immunoregulatory Antibiotics Guttiferae Extract Disease Research Anticancer
Target:
Synonyms: 5-(4-Phenylbutoxy)psoralen
Research Areas:
Psora-4 (5-(4-Phenylbutoxy) psoralen) is a selective Kv1.3 blocker (Kd = 3 nM). Psora-4 increases mitochondrial ROS production, activates stress response genes including daf-16 targets and heat shock proteins, reduces triglyceride accumulation, extends lifespan and healthspan in C. elegans, and increases resistance to Paraquat-induced oxidative stress. Psora-4 can be used for research on psoriasis and obesity .
Research Areas:
12(R)-HETE is a CYP-dependent arachidonic acid metabolite that acts as a proinflammatory lipid mediator. 12 (R)-HETE widely exists in various tissues including the eye, skin and liver. In the cornea, 12(R)-HETE is metabolized via pathways such as β-oxidation into the precursor of 12(R)-HETrE. Without direct receptor binding, 12(R)-HETE indirectly activates AHR-mediated target gene transcription, while inhibiting the enzymatic activity of Na+,K+-ATPase and the intracellular calcium elevation induced by TP agonists. 12(R)-HETE also possesses multiple physiological effects such as chemotaxis, proangiogenesis, vasodilation, natriuresis, diuresis and intraocular pressure reduction, and can be widely used in studies related to psoriasis, inflammatory skin diseases and ocular inflammation .
Cat. No.: HY-155978
CAS No.: 2839429-51-3
Target:
Research Areas:
RDN2150 is a ZAP-70 inhibitor with an IC50 of 14.6 nM, and it exhibits selectivity for Syk over other kinases. RDN2150 inhibits signal transduction and activation of T cells/CAR-T cells, reduces the phosphorylation level of Erk1/2, suppresses the induction of CD69 and IL-2, and downregulates phosphotyrosine signaling pathways including hnRNP sites in T cells. RDN2150 can be used for psoriasis-related research .
Cat. No.: HY-178166
CAS No.: 2773474-99-8
Research Areas:
ETI41 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 (IC50 = 0.63 μM) and TLR9 (IC50 = 0.16 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI41 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI41 suppresses the expression of inflammation-associated genes and effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI41 can be used for autoimmune and inflammatory diseases research .
Cat. No.: HY-A0150
CAS No.: 67452-97-5
Synonyms: 7a-Chloro-16a-methyl prednisolone
Target:
Research Areas:
Alclometasone (7a-Chloro-16a-methyl prednisolone) is a glucocorticoid and inhibits the release of pro-inflammatory mediators from leukocytes. Alclometasone can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis, eczema, psoriasis and allergic dermatitis .
Cat. No.: HY-178169
CAS No.: 2773475-11-7
Research Areas:
ETI60 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 (IC50 = 0.68 μM) and TLR9 (IC50 = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI60 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI60 modulates the expression of genes associated with inflammation. ETI60 effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI60 can be used for autoimmune and inflammatory diseases research .
Cat. No.: HY-178053
CAS No.: 1191937-43-5
Research Areas:
AHR agonist 10 is a potent AHR agonist (EC50 = 2.01 nM). AHR agonist 10 can elevate the transcript levels of key AHR downstream pathway target genes, including CYP1A1 and CYP1B1. AHR agonist 10 can downregulate the expression levels of CD36, IL-18 and shows low cytotoxicity (>40 μM) to normal cells. AHR agonist 10 can suppress the expression of CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α, and TNFR1, demonstrating that AHR agonist 10 effectively modulate inflammatory responses through AHR dependent signaling pathways. AHR agonist 10 can be used for psoriasis research .
Cat. No.: HY-B1616R
CAS No.: 25122-57-0
Research Areas:
Clobetasone butyrate (Standard) is the analytical standard of Clobetasone butyrate. This product is intended for research and analytical applications. Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
Target:
Research Areas:
IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
Cat. No.: HY-115676
CAS No.: 2048226-46-4
Target:
Research Areas:
GSK199 analog hydrochloride belongs to a class of compounds that inhibit PAD4 (guanidinoarginine deiminase 4). GSK199 analog hydrochloride has potential uses in diseases including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis .
Cat. No.: HY-141535
CAS No.: 2446803-85-4
Target:
Research Areas:
IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
Cat. No.: HY-176520
CAS No.: 2815361-45-4
Target:
Research Areas:
PDE4-IN-29 (Compound 55) is an orally active and selective PDE4 inhibitor (including subtypes such as PDE4A1, PDE4B2, PDE4D3) with IC50s of <5 nM against PDE4D3. PDE4-IN-29 inhibits the degradation of cyclic adenosine monophosphate (cAMP), increases intracellular cAMP levels, suppressing the release of inflammatory factors such as TNF-α. PDE4-IN-29 is promising for research of inflammatory diseases including psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease .
Cat. No.: HY-116330AR
CAS No.: 238074-03-8
Synonyms: Hyperforin DCHA (Standard)
Cat. No.: HY-181708
CAS No.: 3113890-51-7
Target:
PROTACs IRAK TNF Receptor IFNAR Interleukin Related CXCR CCR
Research Areas:
PROTAC IRAK4 degrader-14 is an orally active IRAK4 PROTAC degrader with a DC50 of 2.4 nM. PROTAC IRAK4 degrader-14 inhibits proinflammatory responses in multiple cell types including T cells, monocytes and keratinocytes. PROTAC IRAK4 degrader-14 is applicable to research related to psoriasis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
